Chengdu Kanghong Pharmaceuticals Group Co Ltd Working Capital to Net Assets Ratio
Chengdu Kanghong Pharmaceuticals Group Co Ltd working capital to net assets ratio. Chengdu Kanghong Pharmaceuticals Group Co Ltd (002773) has a Working Capital to Net Assets ratio of 70.2% as of June 2026. Working capital of CN¥6.44 Billion (current assets of CN¥7.15 Billion minus current liabilities of CN¥712.99 Million) is measured against net assets of CN¥9.18 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check Chengdu Kanghong Pharmaceuticals Group C tangible book value ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Chengdu Kanghong Pharmaceuticals Group Co Ltd (2009–2025)
Working capital to net assets ratio of Chengdu Kanghong Pharmaceuticals Group Co Ltd from 2009 to 2025. This chart shows how Chengdu Kanghong Pharmaceuticals Group Co Ltd's Working Capital to Net Assets ratio has evolved across 17 annual periods from 2009 to 2025. As of June 2026, the ratio stands at 70.2%, reflecting working capital of CN¥6.44 Billion against net assets of CN¥9.18 Billion CNY. See 002773 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Chengdu Kanghong Pharmaceuticals Group Co Ltd Working Capital to Net Assets Ratio by Year (2009–2025)
Chengdu Kanghong Pharmaceuticals Group Co Ltd working capital to net assets ratio by year from 2009 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Chengdu Kanghong Pharmaceuticals Group Co Ltd from 2009 to 2025, covering 17 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see 002773 total assets.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 69.9% | CN¥6.48 Billion | CN¥9.27 Billion | CN¥7.08 Billion | CN¥601.72 Million | ▲ +4.7 pp |
| 2024 | 65.2% | CN¥5.63 Billion | CN¥8.65 Billion | CN¥6.29 Billion | CN¥654.99 Million | ▲ +5.6 pp |
| 2023 | 59.5% | CN¥4.65 Billion | CN¥7.81 Billion | CN¥5.31 Billion | CN¥654.43 Million | ▲ +8.4 pp |
| 2022 | 51.2% | CN¥3.54 Billion | CN¥6.91 Billion | CN¥4.23 Billion | CN¥693.66 Million | ▲ +1.5 pp |
| 2021 | 49.7% | CN¥3.03 Billion | CN¥6.10 Billion | CN¥3.70 Billion | CN¥667.37 Million | ▼ -2.1 pp |
| 2020 | 51.8% | CN¥2.98 Billion | CN¥5.76 Billion | CN¥3.96 Billion | CN¥980.62 Million | ▲ +2.5 pp |
| 2019 | 49.3% | CN¥2.28 Billion | CN¥4.62 Billion | CN¥3.03 Billion | CN¥747.17 Million | ▼ -19.1 pp |
| 2018 | 68.4% | CN¥2.79 Billion | CN¥4.08 Billion | CN¥3.41 Billion | CN¥619.97 Million | ▼ -13.0 pp |
| 2017 | 81.4% | CN¥2.88 Billion | CN¥3.54 Billion | CN¥3.46 Billion | CN¥579.35 Million | ▲ +2.8 pp |
| 2016 | 78.6% | CN¥2.28 Billion | CN¥2.90 Billion | CN¥2.88 Billion | CN¥592.62 Million | ▲ +4.9 pp |
| 2015 | 73.7% | CN¥1.86 Billion | CN¥2.52 Billion | CN¥2.14 Billion | CN¥280.74 Million | ▲ +14.3 pp |
| 2014 | 59.4% | CN¥957.83 Million | CN¥1.61 Billion | CN¥1.19 Billion | CN¥230.84 Million | ▲ +8.5 pp |
| 2013 | 50.9% | CN¥707.49 Million | CN¥1.39 Billion | CN¥916.75 Million | CN¥209.26 Million | ▲ +14.2 pp |
| 2012 | 36.7% | CN¥405.73 Million | CN¥1.11 Billion | CN¥671.59 Million | CN¥265.85 Million | ▲ +10.8 pp |
| 2011 | 25.9% | CN¥242.39 Million | CN¥936.39 Million | CN¥508.48 Million | CN¥266.09 Million | ▲ +16.0 pp |
| 2010 | 9.9% | CN¥61.96 Million | CN¥624.85 Million | CN¥343.30 Million | CN¥281.34 Million | ▼ -23.4 pp |
| 2009 | 33.4% | CN¥180.02 Million | CN¥539.75 Million | CN¥392.30 Million | CN¥212.28 Million | — |